161 related articles for article (PubMed ID: 30651019)
1. The five-year effects of testosterone replacement therapy on lipid profile and glucose tolerance among hypogonadal men in Japan: a case control study.
Kato Y; Shigehara K; Nakashima K; Iijima M; Kawagushi S; Nohara T; Izumi K; Kadono Y; Konaka H; Namiki M; Mizokami A
Aging Male; 2020 Mar; 23(1):23-28. PubMed ID: 30651019
[No Abstract] [Full Text] [Related]
2. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
4. Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study).
Shigehara K; Konaka H; Koh E; Nakashima K; Iijima M; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Sugimoto K; Iwamoto T; Mizokami A; Namiki M
Aging Male; 2017 Sep; 20(3):139-145. PubMed ID: 28347184
[TBL] [Abstract][Full Text] [Related]
5. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus.
Shigehara K; Konaka H; Kato Y; Iijima M; Nakashima K; Kawaguchi S; Nohara T; Izumi K; Namiki M; Mizokami A
Int J Impot Res; 2019 Jan; 31(1):25-30. PubMed ID: 30135606
[TBL] [Abstract][Full Text] [Related]
6. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
7. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
8. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
9. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate.
Choi EJ; Xu P; Barham D; El-Khatib FM; Yafi FA; Kavoussi PK
J Urol; 2022 Mar; 207(3):677-683. PubMed ID: 34694927
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
12. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
15. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
16. Effects of testosterone replacement therapy on nocturia and quality of life in men with hypogonadism: a subanalysis of a previous prospective randomized controlled study in Japan.
Shigehara K; Konaka H; Koh E; Izumi K; Kitagawa Y; Mizokami A; Nakashima T; Shimamura M; Iwamoto T; Namiki M
Aging Male; 2015; 18(3):169-74. PubMed ID: 26075538
[TBL] [Abstract][Full Text] [Related]
17. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
19. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
